Yuce Bio Completes Tens of Millions RMB Pre-B+ Financing to Accelerate Early Screening and Diagnosis Market for Alzheimer's Disease

VCBeat has learned that Suzhou ASTRABIO Biotechnology Co., Ltd. (“ASTRABIO”) recently completed a Pre-B+ financing round worth tens of millions of yuan, exclusively invested by LH Ventures. Since 2024, ASTRABIO has secured nearly RMB 100 million in consecutive funding rounds. The company continues to build a premium domestic brand for next-generation immunoassay technologies centered on neurological biomarkers, accelerating its market expansion in the early screening and diagnosis of Alzheimer’s disease.

Neurodegenerative diseases driven by global population aging can no longer be overlooked. Neurodegenerative conditions, led by Alzheimer’s disease, have imposed substantial physical, psychological, and economic burdens on many families. Effective early screening, diagnosis, and treatment have become critically important. The market launch of a series of Alzheimer’s therapeutics, spearheaded by Lecanemab, signifies that the long-missing treatment component in the Alzheimer’s care business model has finally been completed, closing the loop. The neuroscience diagnostics and therapeutics market, with Alzheimer’s disease at its forefront, is now poised for robust growth.

Leveraging its independently developed single-molecule immunoassay platform, ASTRABIO has taken the lead in positioning itself within China’s market for neurological blood-based biomarkers. By establishing an efficient “industry-academia-research” translation platform, the company is building a premium technology brand and enhancing its academic influence to advance the clinical translation and market adoption of novel biomarkers centered on neuroscience. Furthermore, ASTRABIO has forged deep collaborations with multiple leading hospitals across China and published numerous high-impact academic papers.

Leveraging years of technological accumulation and product line integration, the company has established a comprehensive presence in Alzheimer’s disease (AD) screening, physical examinations, and diagnostics. It offers a full range of commercialized kits covering core AD biomarkers for market launch, driving the standardization of single-molecule technology in neurological blood biomarkers and establishing significant industry barriers in single-molecule immunoassay-based AD blood testing. ASTRABIO’s single-molecule immunoassay products are utilized by leading research institutions and top-tier clinical facilities, underscoring the company’s leadership in the application field of neurological disorders.

ASTRABIO's Novel Biomarker Research-to-Clinical Translation Platform

Neurobiological markers are present in blood at extremely low concentrations, typically at the pg/mL or even fg/mL level. Traditional immunoassay methods are limited by their sensitivity, making accurate quantification difficult and hindering widespread clinical application. Single-molecule immunoassay technology, with its ultra-high detection sensitivity, has truly enabled precise detection and clinical application of neurobiomarkers in blood. ASTRABIO has built a comprehensive ultra-sensitive biomarker platform for research-to-clinical translation based on single-molecule immunoassay technology. The development of this new technology will open up a blue-ocean opportunity worth tens of billions in the IVD market for ultra-sensitive biomarkers.

ASTRABIO has filed over 40 core patent applications, with more than 20 already granted. It holds China’s first invention patent for single-molecule technology. Its PCT patents have been granted in China, Japan, Canada, and Australia, while applications are concurrently pending in the United States, the European Union, and other countries and regions. The company has established collaborations with multiple international enterprises on diagnostic products for neuro-blood biomarkers based on single-molecule immunoassay technology. In addition to actively advancing its global commercialization strategy, ASTRABIO is intensifying efforts in global product registration, building a global operational framework, optimizing its global supply chain management, and strengthening cooperation with international research institutions to jointly conduct frontier technological research and application development focused on neuro-blood biomarkers. These initiatives aim to establish ASTRABIO as a globally recognized brand with international influence.

Li Qiuxuan, Vice President of LH VenturesStatement: We are highly optimistic about the future clinical expansion and application of single-molecule immunoassay technology. Currently, many disease-related biomarkers remain underexplored, and ultra-sensitive protein detection platforms offer new possibilities in this regard. In particular, this technology has demonstrated significant potential in blood-based testing for Alzheimer’s disease (AD). As AD therapeutics continue to gain regulatory approval, early screening, diagnosis, and treatment are expected to form a complete industrial loop, which will further drive the clinical development of this technology. We are pleased to collaborate with ASTRABIO. The company’s independently developed single-molecule immunoassay platform has achieved comprehensive coverage in China’s clinical and research markets and holds a leading position in its niche sector. We look forward to the company not only achieving success in the domestic market but also securing a prominent place in the global market.

Guan Zhichao, Founder of ASTRABIOStatement: We are deeply honored to receive investment from LH Ventures. In the current capital winter, such timely support is far more valuable and rare than mere锦上添花 (icing on the cake). Since the beginning of this year, ASTRABIO has completed successive financing rounds totaling nearly RMB 100 million, which will further accelerate our brand building and advance the commercial deployment of our products. The company has already established partnerships with over ten top-tier benchmark hospitals, cementing its position as a leading brand in its niche sector, and has made initial progress in its overseas business expansion. The single-molecule immunoassay technology developed by the company offers ultra-high detection sensitivity, creating new opportunities in the traditional immunoassay market. With a core focus on the clinical application of neurological biomarkers, the company leverages its platform advantages to continuously promote the clinical translation and application of novel ultra-sensitive biomarkers.

Founded in 2019, ASTRABIO (Suzhou Yuce Biotechnology Co., Ltd.) operates an R&D and production center spanning nearly 8,000 square meters. As a high-tech enterprise dedicated to the industrialization of single-molecule immunoassay technology, the company holds full independent intellectual property rights for its core technologies, successfully filling a gap at the forefront of this field in China. Guided by the vision to “become a trusted supporter and leader in the life and health sector,” and upholding the mission to “advance human health through precise diagnostics and create an infinite future through technological innovation,” ASTRABIO leverages its core single-molecule immunoassay technology to focus on the development and clinical translation of novel biomarkers, poised to drive the next generation of transformative advances in immunoassay technology.

LH Ventures, co-founded by scientists, entrepreneurs, and seasoned investors in 2018, focuses on venture capital in the fields of intelligent technology and biomedicine. With offices in Chongqing, Shanghai, San Francisco, and Boston, LH Ventures manages multiple RMB and USD funds with a total asset value of approximately RMB 2.8 billion. We are committed to realizing the value of hard technology by working alongside scientists and entrepreneurs, adhering to the principles of pragmatism and innovation, and jointly building outstanding technology-driven enterprises.